Ciclesonide Inhaler Treatment for Mild-to-Moderate COVID-19: A Randomized, Open-Label, Phase 2 Trial
Article
[키워드] 95% confidence interval
acute respiratory syndrome
adverse event
Analysis
antiviral agent
Antiviral agents
assigned
Ciclesonide
clinical
clinical trial
conducted
coronavirus
coronavirus disease
COVID-19
Diagnosis
drug
effective
Efficacy
enrolled
evaluate
evaluated
groups
High-flow nasal oxygen
inhalation
inhaler
inhibit
intravenous
mechanical ventilation
Mild-to-moderate
multicenter
nasopharyngeal viral load
Negative conversion
Open-label
Patient
per day
Phase 2
polymerase chain
primary endpoint
progression
Quantitative
Randomized
Randomly
receive
Registration
Respiratory failure
reverse transcription
SARS-CoV-2
SARS-CoV-2 viral shedding
significantly higher
significantly lower
standard care
study enrollment
symptom onset
therapy
treat
Treatment
[DOI] 10.3390/jcm10163545 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/jcm10163545 PMC 바로가기 [Article Type] Article